GlaxoSmithKline PLC is poised to take back control of some of its biggest OTC brands in South Korea as part of a portfolio review triggered by the launch of its consumer healthcare joint venture with Pfizer Inc..
The UK-based firm has terminated ahead of schedule a sales and distribution deal with Dongwha Pharmaceutical in a move which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?